Drugs / [68Ga]Ga-DOTA-TOC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07178938 | Apr → Nov 2026 expected | HER2 positive breast carcinoma | MedSIR | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-DOTA-TOC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07178938 ↗ |
| Modality | Diagnostic / imaging agent | “diagnostic agent” NCT07178938 ↗ |
| Route | Intravenous | “administered by direct slow intravenous injection” NCT07178938 ↗ |